gene_symbol
FCGR3A
hgnc_id
HGNC:3619
binding_type
receptor ligand recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
Elotuzumab’s Fc binds CD16a (FcγRIIIa) on NK cells to activate them; these NK cells then mediate ADCC against SLAMF7-positive tumor cells. CD16a-expressing cells are not killed by the drug.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Fc-mediated engagement on NK cells to drive ADCC
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT05560399
disease_id_num_tar_ref
5226
drug_id_num_tar_ref
14181